Current vaccine updates for lung cancer

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin.59(4), 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J. Thorac. Cardiovasc. Surg.96(3), 440–447 (1988).
   PubMed Web of Science ®Google Scholar
• Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest130(4), 1211–1219 (2006).
   PubMed Web of Science ®Google Scholar
• Krasna MJ, Reed CE, Nugent WC et al. Lung cancer staging and treatment in multidisciplinary trials: cancer and leukemia group B co-operative group approach. Ann. Thorac. Surg.68, 201–207 (1999).
   PubMed Web of Science ®Google Scholar
• Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin. Biol. Ther.8(7), 951–968 (2008).
   PubMed Web of Science ®Google Scholar
• Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol.24(24), 3831–3837 (2006).
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol.168(9), 4272–4276 (2002).
   PubMed Web of Science ®Google Scholar
• Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer65(1), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Galceran J, Marcos-Gragera R, Soler M et al. Cancer incidence in AIDS patients in Catalonia, Spain. Eur. J. Cancer43(6), 1085–1091 (2007).
   Google Scholar
• Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS21(2), 207–213 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshino I, Yano T, Murata M et al. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res.52(4), 775–781 (1992).
   PubMed Web of Science ®Google Scholar
• McCracken JD, Chen T, White J et al. Combination chemotherapy, radiotherapy, and BCG immunotherapy in limited small-cell carcinoma of the lung: a Southwest Oncology Group Study. Cancer49(11), 2252–2258 (1982).
   PubMed Web of Science ®Google Scholar
• Matthay RA, Mahler DA, Beck GJ et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res.46(11), 5963–5968 (1986).
   PubMed Web of Science ®Google Scholar
• Van den Heuvel MM, Burgers SA, van Zandwijk N. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. Clin. Lung Cancer10(2), 99–105 (2009).
   PubMed Web of Science ®Google Scholar
• Lucas S, Coulie PG. About human tumor antigens to be used in immunotherapy. Semin. Immunol.20(5), 301–307 (2008).
   PubMed Web of Science ®Google Scholar
• Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J. Thorac. Oncol.3(6 Suppl. 2), S164–S170 (2008).
   PubMed Web of Science ®Google Scholar
• Raez LE, Fein S, Podack ER. Lung cancer immunotherapy. Clin. Med. Res.3(4), 221–228 (2005).
   Google Scholar
• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother.54(3), 187–207 (2005).
   PubMed Web of Science ®Google Scholar
• Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol.21(12), 2415–2432 (2003).
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Todryk SM, Dalgleish AG. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol. Immunother.51(10), 521–531 (2002).
   PubMed Web of Science ®Google Scholar
• Ho C, Ochsenbein AF, Gautschi O, Davies AM. Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clin. Lung Cancer9(Suppl. 1), S20–S27 (2008).
   Google Scholar
• Pozniak A, Stanford JL, Grange JM. Mycobacterium vaccae immunotherapy. Lancet338(8781), 1533–1534 (1991).
   Google Scholar
• Prior JG, Khan AA, Cartwright KA, Jenkins PA, Stanford JL. Immunotherapy with Mycobacterium vaccae combined with second line chemotherapy in drug-resistant abdominal tuberculosis. J. Infect.31(1), 59–61 (1995).
   PubMedGoogle Scholar
• Shirtcliffe PM, Easthope SE, Cheng S et al. The effect of delipidated deglycolipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am. J. Respir. Crit. Care Med.163(6), 1410–1414 (2001).
   PubMed Web of Science ®Google Scholar
• Altundag K, Mohamed AS, Altundag O, Silay YS, Gunduz E, Demircan K. SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients. Med. Hypotheses64(2), 248–251 (2005).
   Google Scholar
• Grange JM, Bottasso O, Stanford CA, Stanford JL. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine26(39), 4984–4990 (2008).
   PubMedGoogle Scholar
• O’Brien ME, Saini A, Smith IE et al. A randomized Phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br. J. Cancer83(7), 853–857 (2000).
   PubMedGoogle Scholar
• O’Brien ME, Anderson H, Kaukel E et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann. Oncol.15(6), 906–914 (2004).
   PubMed Web of Science ®Google Scholar
• Stanford JL, Stanford CA, O’Brien ME, Grange JM. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur. J. Cancer44(2), 224–227 (2008).
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Lyerly HK. Handbook of Cancer Vaccines. Humana Press Inc., NJ, USA (2004).
   Google Scholar
• Brichard VG, Lejeune D. GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine25(Suppl. 2), B61–B71 (2007).
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Altorki NK, Stockert E et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol.172(5), 3289–3296 (2004).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Betticher D, Eberhardt W, De Leyn P. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J. Thorac. Oncol.2(8), 684–685 (2007).
   PubMedGoogle Scholar
• Atanackovic D, Altorki NK, Cao Y et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl Acad. USA105(5), 1650–1655 (2008).
   PubMed Web of Science ®Google Scholar
• Ho SB, Niehans GA, Lyftogt C et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res.53(3), 641–651 (1993).
   PubMed Web of Science ®Google Scholar
• Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol.82, 249–293 (2004).
   PubMed Web of Science ®Google Scholar
• Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol.23(27), 6674–6681 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Crombet T, Catala M et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol.9(4), 431–435 (1998).
   PubMed Web of Science ®Google Scholar
• Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol. Immunother.47(1), 1–12 (1998).
   PubMed Web of Science ®Google Scholar
• Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin. Cancer Res.13(15 Pt 2), S4652–S4654 (2007).
   PubMed Web of Science ®Google Scholar
• Ramlau R, Quoix E, Rolski J et al. A Phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J. Thorac. Oncol.3(7), 735–744 (2008).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene19(56), 6550–6565 (2000).
   PubMed Web of Science ®Google Scholar
• Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin. Cancer Res.12(14 Pt 2), S4441–S4445 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann. Oncol.14, 461–466 (2003).
   PubMed Web of Science ®Google Scholar
• Neninger Vinageras E, de la Torre A, Osorio Rodriguez M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J. Clin. Oncol.26(9), 1452–1458 (2008).
   PubMed Web of Science ®Google Scholar
• Neninger E, Verdecia BG, Crombet T et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother.32(1), 92–99 (2009).
   PubMed Web of Science ®Google Scholar
• West HJ. Novel targeted agents for lung cancer. Clin. Lung Cancer10(Suppl. 1), S41–S46 (2009).
   PubMed Web of Science ®Google Scholar
• Schroers R, Shen L, Rollins L et al. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin. Cancer Res.9(13), 4743–4755 (2003).
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity10(6), 673–679 (1999).
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Palma M, Hansson L, Osterborg A, Mellstedt H, Choudhury A. Telomerase (hTERT 611–626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp. Hematol.35(2), 297–304 (2007).
   PubMed Web of Science ®Google Scholar
• Bernhardt SL, Gjertsen MK, Trachsel S et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating Phase I/II study. Br. J. Cancer95(11), 1474–1482 (2006).
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Aamdal S, Gjertsen MK et al. Telomerase peptide vaccination: a Phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother.55(12), 1553–1564 (2006).
   PubMed Web of Science ®Google Scholar
• Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin. Investig. Drugs18(5), 687–694 (2009).
   PubMed Web of Science ®Google Scholar
• Malykh YN, Schauer R, Shaw L. N-glycolylneuraminic acid in human tumours. Biochimie83(7), 623–634 (2001).
   PubMed Web of Science ®Google Scholar
• Vazquez AM, Gabri MR, Hernandez AM et al. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol. Rep.7(4), 751–756 (2000).
   PubMed Web of Science ®Google Scholar
• Irie A, Suzuki A. CMP-N-acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem. Biophys. Res. Commun.248(2), 330–333 (1998).
   Google Scholar
• Vazquez AM, Perez A, Hernandez AM et al. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma17(6), 527–534 (1998).
   PubMedGoogle Scholar
• Alfonso M, Diaz A, Hernandez AM et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol.168(5), 2523–2529 (2002).
   PubMed Web of Science ®Google Scholar
• Neninger E, Diaz RM, de la Torre A et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a Phase I trial. Cancer Biol. Ther.6(2), 145–150 (2007).
   PubMed Web of Science ®Google Scholar
• Diaz A, Alfonso M, Alonso R et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin. Immunol.107(2), 80–89 (2003).
   PubMed Web of Science ®Google Scholar
• Alfonso S, Diaz RM, de la Torre A et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol. Ther.6(12), 1847–1852 (2007).
   PubMed Web of Science ®Google Scholar
• Hernandez AM, Toledo D, Martinez D et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J. Immunol.181(9), 6625–6634 (2008).
   PubMed Web of Science ®Google Scholar
• Slodkowska J, Szturmowicz M, Rudzinski P et al. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels. Eur. J. Cancer Prev.7(1), 51–60 (1998).
   PubMed Web of Science ®Google Scholar
• Fijolek J, Wiatr E, Rowinska-Zakrzewska E et al. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int. J. Biol. Markers21(2), 81–87 (2006).
   Google Scholar
• Tsao MS, Aviel-Ronen S, Ding K et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol.25(33), 5240–5247 (2007).
   PubMed Web of Science ®Google Scholar
• Brabender J, Danenberg KD, Metzger R et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res.7(7), 1850–1855 (2001).
   PubMed Web of Science ®Google Scholar
• Vallbohmer D, Brabender J, Yang DY et al. Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer. Clin. Lung Cancer7(5), 332–337 (2006).
   PubMed Web of Science ®Google Scholar
• Sienel W, Varwerk C, Linder A et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur. J. Cardiothorac. Surg.25(1), 131–134 (2004).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol.18(23), 3964–3973 (2000).
   PubMed Web of Science ®Google Scholar
• Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. USA98(15), 8809–8814 (2001).
   PubMed Web of Science ®Google Scholar
• Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest.107(4), 477–484 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med.4(3), 321–327 (1998).
   PubMed Web of Science ®Google Scholar
• Arlen P, Tsang KY, Marshall JL et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol. Immunother.49(10), 517–529 (2000).
   PubMed Web of Science ®Google Scholar
• Horig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother.49(9), 504–514 (2000).
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Nijman HW, Offringa R et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med.186(5), 695–704 (1997).
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Bos GM, Ooms M, Offringa R, Melief CJ. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int. J. Cancer87(2), 253–260 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenwirth B, Kuhn EM, Heeney JL et al. Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine19(13–14), 1661–1670 (2001).
   PubMed Web of Science ®Google Scholar
• van der Burg SH, de Cock K, Menon AG et al. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur. J. Immunol.31(1), 146–155 (2001).
   PubMed Web of Science ®Google Scholar
• Ferries E, Connan F, Pages F et al. Identification of p53 peptides recognized by CD8+ T lymphocytes from patients with bladder cancer. Hum. Immunol.62(8), 791–798 (2001).
   PubMed Web of Science ®Google Scholar
• Tartaglia J, Bonnet MC, Berinstein N, Barber B, Klein M, Moingeon P. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine19(17–19), 2571–2575 (2001).
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science254(5038), 1643–1647 (1991).
   PubMed Web of Science ®Google Scholar
• Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med.190(11), 1669–1678 (1999).
   PubMed Web of Science ®Google Scholar
• Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A Phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund’s adjuvant in patients with resected high-risk melanoma. J. Immunother.22(5), 431–440 (1999).
   PubMed Web of Science ®Google Scholar
• Coulie PG, Karanikas V, Colau D et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl Acad. USA98(18), 10290–10295 (2001).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res.61(17), 6451–6458 (2001).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244(4905), 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Disis ML, Calenoff E, McLaughlin G et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res.54(1), 16–20 (1994).
   PubMed Web of Science ®Google Scholar
• Alexander J, Sidney J, Southwood S et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity1(9), 751–761 (1994).
   PubMed Web of Science ®Google Scholar
• Barve M, Bender J, Senzer N et al. Induction of immune responses and clinical efficacy in a Phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J. Clin. Oncol.26(27), 4418–4425 (2008).
   PubMed Web of Science ®Google Scholar
• Ishioka GY, Disis ML, Morse MA et al. Multi-epitope CTL responses induced by a peptide vaccine (EP-2101) in colon and non-small cell lung cancer patients. J. Immunother.27(6), S23–S24 (2004) (Abstract).
   Google Scholar
• Border WA, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J. Clin. Invest.90(1), 1–7 (1992).
   PubMed Web of Science ®Google Scholar
• Jakowlew SB, Mathias A, Chung P, Moody TW. Expression of transforming growth factor β ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ.6(4), 465–476 (1995).
   PubMedGoogle Scholar
• Kasid A, Bell GI, Director EP. Effects of transforming growth factor-β on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J. Immunol.141(2), 690–698 (1988).
   PubMed Web of Science ®Google Scholar
• Massague J. The TGF-β family of growth and differentiation factors. Cell49(4), 437–438 (1987).
   PubMed Web of Science ®Google Scholar
• Naganuma H, Sasaki A, Satoh E et al. Transforming growth factor-β inhibits interferon-γ secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol. Med. Chir. (Tokyo)36(11), 789–795 (1996).
   PubMedGoogle Scholar
• Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer86(9), 1712–1719 (1999).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol.24(29), 4721–4730 (2006).
   PubMed Web of Science ®Google Scholar
• Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res.57(15), 3200–3207 (1997).
   PubMed Web of Science ®Google Scholar
• Fakhrai H, Mantil JC, Liu L et al. Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther.13(12), 1052–1060 (2006).
   PubMed Web of Science ®Google Scholar
• Park JA, Wang E, Kurt RA, Schluter SF, Hersh EM, Akporiaye ET. Expression of an antisense transforming growth factor-β1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther.4(1), 42–50 (1997).
   PubMed Web of Science ®Google Scholar
• Tzai TS, Shiau AL, Liu LL, Wu CL. Immunization with TGF-β antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions. Anticancer Res.20(3A), 1557–1562 (2000).
   PubMed Web of Science ®Google Scholar
• Rook AH, Kehrl JH, Wakefield LM et al. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol.136(10), 3916–3920 (1986).
   PubMed Web of Science ®Google Scholar
• Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-β. Nature334(6179), 260–262 (1988).
   PubMed Web of Science ®Google Scholar
• Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-β: biological function and chemical structure. Science233(4763), 532–534 (1986).
   PubMed Web of Science ®Google Scholar
• Bodmer S, Strommer K, Frei K et al. Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β 2. J Immunol,143(10), 3222–3229 (1989).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Nemunaitis M, Senzer N et al. Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther.16(8), 620–624 (2009).
   PubMed Web of Science ®Google Scholar
• Warren TL, Weiner GJ. Uses of granulocyte–macrophage colony-stimulating factor in vaccine development. Curr. Opin. Hematol.7(3), 168–173 (2000).
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. USA90(8), 3539–3543 (1993).
   PubMed Web of Science ®Google Scholar
• Salgia R, Lynch T, Skarin A et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte–macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol.21(4), 624–630 (2003).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Nemunaitis J. Granulocyte–macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus [correction to fcous] on non-small-cell lung cancer. Clin. Lung Cancer5(3), 148–157 (2003).
   PubMedGoogle Scholar
• Nemunaitis J, Jahan T, Ross H et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther.13(6), 555–562 (2006).
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Seigne J, Diaz J et al. Phase I trial of a B7–1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urology167(5), 1995–2000 (2002).
   PubMed Web of Science ®Google Scholar
• Raez LE, Cassileth PA, Schlesselman JJ et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J. Clin. Oncol.22(14), 2800–2807 (2004).
   PubMed Web of Science ®Google Scholar
• Raez LE, Santos ES, Mudad R, Podack ER. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. Expert Rev. Anticancer Ther.5(4), 635–644 (2005).
   PubMed Web of Science ®Google Scholar
• Deriy L, Ogawa H, Gao GP, Galili U. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the α1,3galactosyltransferase gene. Cancer Gene Ther.12(6), 528–539 (2005).
   Google Scholar
• Morris JC, Vahanian N, Janik JE. Phase I study of an antitumor vaccination using α(1,3)galactosyltransferase expressing allogeneic tumor cells in patients (Pts) with refractory or recurrent non-small cell lung cancer (NSCLC). 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol.23(16S, Pt 1, Suppl.), 2586 (2005).
   PubMed Web of Science ®Google Scholar
• Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol. Immunother.53(4), 275–306 (2004).
   PubMed Web of Science ®Google Scholar
• Conrad C, Nestle FO. Dendritic cell-based cancer therapy. Curr. Opin. Mol. Ther.5(4), 405–412 (2003).
   PubMed Web of Science ®Google Scholar
• Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol.22(14), 2808–2815 (2004).
   PubMed Web of Science ®Google Scholar
• Ueda Y, Itoh T, Nukaya I et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int. J. Oncol.24(4), 909–917 (2004).
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Hobeika AC et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res.11(8), 3017–3024 (2005).
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika AC, Osada T et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood112(3), 610–618 (2008).
   PubMed Web of Science ®Google Scholar
• Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc. Am. Thorac. Soc.6(2), 224–232 (2009).
   PubMedGoogle Scholar
• Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971–08971B; Silva Study). J. Clin. Oncol.23(28), 6854–6864 (2005).
   PubMed Web of Science ®Google Scholar
• Brezicka T, Bergman B, Olling S, Fredman P. Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues. Lung Cancer28(1), 29–36 (2000).
   PubMed Web of Science ®Google Scholar
• Vangsted AJ, Clausen H, Kjeldsen TB et al. Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) antigen in serum. Cancer Res.51(11), 2879–2884 (1991).
   PubMed Web of Science ®Google Scholar
• Dickler MN, Ragupathi G, Liu NX et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res.5(10), 2773–2779 (1999).
   PubMed Web of Science ®Google Scholar
• Krug LM, Ragupathi G, Hood C et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res.10(18 Pt 1), 6094–6100 (2004).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Hood C, Krug LM et al. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol. Immunother.54(10), 1018–1025 (2005).
   PubMed Web of Science ®Google Scholar
• Rutishauser U. Polysialic acid and the regulation of cell interactions. Curr. Opin. Cell Biol.8(5), 679–684 (1996).
   PubMedGoogle Scholar
• Daniel L, Trouillas J, Renaud W et al. Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar–Furth rats) is related to growth rate and malignancy. Cancer Res.60(1), 80–85 (2000).
   PubMed Web of Science ®Google Scholar
• Krug LM, Ragupathi G, Ng KK et al. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin. Cancer Res.10(3), 916–923 (2004).
   PubMed Web of Science ®Google Scholar
• Roses RE, Xu M, Koski GK, Czerniecki BJ. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene27(2), 200–207 (2008).
   PubMed Web of Science ®Google Scholar
• Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiat. Oncol. Biol. Phys.63(3), 655–666 (2005).
   PubMed Web of Science ®Google Scholar
• Fidler M, Seba A, Farlow E et al. Tumor survivin expression in locally advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemoradiation followed by surgical resection. J. Clin. Oncol.27, S15 (2009).
   Google Scholar
• Maples P, Kumar P, Oxendine I et al. TAG vaccine: autologous tumor vaccine genetically modified to express GM-CSF and block production of TGFβ2. BioProcessing J.8(1), 38–45 (2009).
   Google Scholar